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Key Points
• The Kd for the association of
FXIII subunits is in the range
of 10210 M, and in plasma
approximately 1% of FXIII-A2
exists in free form.
• The binding site for FXIII-A
is located within the 2
N-terminal sushi domains
of FXIII-B.
Coagulation factor XIII (FXIII) is a heterotetramer consisting of 2 catalytic A subunits
(FXIII-A2) and 2 protective/inhibitory B subunits (FXIII-B2). FXIII-B, a mosaic protein
consisting of 10 sushi domains, significantly prolongs the lifespan of catalytic subunits
in the circulation and prevents their slow progressive activation in plasmatic conditions. In
this study, thebiochemistry of the interactionbetween the 2FXIII subunitswas investigated.
Using a surface plasmon resonance technique and an enzyme-linked immunosorbent
assay–typebinding assay, the equilibriumdissociation constant (Kd) for the interactionwas
established in the range of 10210 M. Based on the measured Kd, it was calculated that in
plasma approximately 1% of FXIII-A2 should be in free form. This value was confirmed
experimentally by measuring FXIII-A2 in plasma samples immunodepleted of FXIII-A2B2.
Free plasma FXIII-A2 is functionally active, and when activated by thrombin and Ca21, it
can cross-link fibrin. In cerebrospinal fluid and tears with much lower FXIII subunit
concentrations, >80% of FXIII-A2 existed in free form. A monoclonal anti-FXIII-B antibody
that prevented the interaction between the 2 subunits reacted with the recombinant combined first and second sushi domains of FXIII-B,
and its epitope was localized to the peptide spanning positions 96 to 103 in the second sushi domain. (Blood. 2014;123(11):1757-1763)
Introduction
Blood coagulation factor XIII (FXIII) is a protransglutaminase that is
converted into an active form (FXIIIa) by the concerted action of
thrombin and Ca21 in the ﬁnal phase of the clotting cascade.
Transglutaminases crosslink peptide chains by e(g-glutamyl)lysyl
bonds, and the main task of FXIIIa is to crosslink ﬁbrin a and g
chains and covalently attach a2-plasmin inhibitor to ﬁbrin. This
mechanism is essential for maintaining hemostasis; it protects
newly formed ﬁbrin from the shear stress of circulating blood and
from degradation by the ﬁbrinolytic machinery. Plasma FXIII
(pFXIII) is a heterotetramer (FXIII-A2B2) consisting of 2 po-
tentially active A subunits (FXIII-A2) and 2 carrier/inhibitory B
subunits (FXIII-B2). FXIII-A2 consists of 4 structural domains
(a b-sandwich domain, a catalytic core domain, and 2 b-barrel
domains) and anN-terminal activation peptide. FXIII-B is amosaic
protein consisting of 10 so-called sushi domains, each held togeth-
er by a pair of disulﬁde bonds. It is a glycoprotein containing
approximately 8.5% carbohydrate. FXIII-A2 also exists in the
cytoplasm of certain cells, particularly platelets and monocytes/
macrophages.1,2
FXIII-A is synthesized by cells of bone marrow origin, whereas
FXIII-B is produced by hepatocytes.3-7 The 2 subunits forma complex
in the plasma; FXIII-B is in excess, and approximately 50% of it exists
in free form,8 very likely as dimer.9,10 Complex formation between the
2 subunits is essential for maintaining normal hemostasis. The main
role of FXIII-B is to prolong the lifespan of FXIII-A in the cir-
culation.11 In FXIII-B–deﬁcient patients, the FXIII-A2 concentra-
tion in the plasma is signiﬁcantly decreased, and due to the low
level of FXIII-A2, these patients present moderate bleeding
diathesis.11-13 This role of FXIII-Bmay be related to the prevention
of a slow progressive activation of FXIII-A2, which may occur in
plasmatic conditions in the absence of FXIII-B.14 Considering the
importance of complex formation between the 2 FXIII subunits,
it is surprising that the biochemistry of their interactions is only
superﬁcially explored. The epitopes involved in the interaction of
the 2 subunits have not been speciﬁed. Although it is generally
accepted that FXIII-A in the circulation is “fully” complexed, this
has not been proven experimentally. So far, 2 values (43 1027M and
8 3 1028 M) have been reported for the apparent equilibrium disso-
ciation constant (Kd).
15,16 However, these values were determined in
enzyme-linked immunosorbent assay (ELISA)-type binding assays
using a relatively high (.1028 M) FXIII-B subunit concentration as
receptor. If total receptor concentrations [Rt]..Kd, then the binding
constant could be signiﬁcantly overestimated.17 Indeed, using the
above 2 binding constants and the mean plasma concentrations of
FXIII-A and FXIII-B subunits, 87% or 55% of pFXIII-A2 should
be in free form, which is evidently not the case. Most recently,
the administration of recombinant FXIII-A2 (rFXIII-A2) has been
introduced as substitution therapy in FXIII-A deﬁciency.18 The fact
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that the long-term survival of rFXIII-A2 in the circulation depends on
its complex formation with the available free FXIII-B2 underlines the
importance of exploring the mechanism of FXIII-A2B2 complex
formation.
In the present study, several aspects of the interaction between
the FXIII subunits was investigated. We determined the Kd for the
interaction and calculated and experimentally determined the con-
centration of free FXIII-A2 in the plasma and other body ﬂuids
(cerebrospinal ﬂuid [CSF] and tears). It was tested if free FXIII-A
present in the plasma was functional. Finally, an anti-FXIII-B
monoclonal antibody that prevented complex formation was pro-
duced and its epitope on FXIII-B was determined.
Methods
Materials
Human thrombin, hirudin, 3,39,5,59-tetramethylbenzidine (TMB) substrate,
bovine serum albumin (BSA) fraction V, horseradish peroxidase (HRP) type
VI, biotinamido-hexanoic acid hydrazide, goat anti-mouse immunoglobulin
G (IgG) (Fc speciﬁc), and trypsin (proteomics grade) were purchased from
SigmaAldrich (St. Louis,MO). Bis(sulfosuccinimidyl)suberate was a product
of Pierce (Rockford, IL). Batroxobin moojeni was purchased from
Pentapharm (Basel, Switzerland). Sheep anti-human FXIII-A and rabbit
anti-human FXIII-B polyclonal antibodies were obtained from Afﬁnity
Biologicals (Ancaster, Canada) and Calbiochem (La Jolla, CA), respectively.
Vectastain ABC reagent was from Vector (Burlingame, CA). HRP-
conjugated anti-rabbit IgG was purchased from Jackson Immunoresearch
Laboratories (Westgrove, PA). Streptavidin-coated microplates were from
Thermo Fisher Scientiﬁc (Vantaa, Finland). Monoclonal anti-FXIII-A and
anti-FXIII-B antibodies were produced in BALB/c mice (see in details in the
supplemental Methods available on the Blood Web site).19,20 IgG was
separated from ascites ﬂuid by afﬁnity chromatography on a protein G
Sepharose column (GEHealthcare, Uppsala, Sweden). For the binding assay,
anti-FXIII-B IgG was biotinylated at the carbohydrate moiety using
biotinamido-hexanoic acid hydrazide reagent.21 CNBr-activated Sepharose
4B gel and CM5 sensor chips were from GE Healthcare.
FXIII preparations and FXIII antigen determinations
Highly puriﬁed human pFXIII22 and pFXIII-B2
23,24 were prepared from
pooled human plasma. Cellular FXIII was prepared from human placenta,14
and rFXIII-A2 was a kind gift from Dr Eva H.N. Olsen (Novo Nordisk,
Ma˚løv, Denmark). Recombinant FXIII-B2 (rFXIII-B2) produced in insect
cells was from Zedira (Darmstadt, Germany). FXIII-A2B2 and FXIII-A2
antigen concentrations were determined as described earlier.19,20
Surface plasmon resonance investigations
Surface plasmon resonance (SPR) investigations were performed on Biacore
X instrument (GEHealthcare). A total of 100 mg/mL pFXIII-B2 or rFXIII-B2
was immobilized to ﬂow cell 2 of a CM5 sensor chip according to the amine
coupling protocol. BSA was used to cover control ﬂow cell 1. Various
concentrations of cellular (placenta) FXIII-A2 (cFXIII-A2) or rFXIII-A2 in
10 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid buffer (pH 7.4)
containing 150 mM NaCl, 3 mM EDTA, and 0.005% volume to volume ratio
(v/v) surfactant were used as analyte. The ﬂow rate through the cells was
10mL/minute.The solutionused for regenerationcontained50U/mL thrombin,
250 mM CaCl2, 10 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic
acid buffer, 150 mMNaCl, and 0.005% v/v surfactant (pH 7.4). In this setup,
after cleaving off the activation peptide by thrombin, the bound FXIII-A2
dissociates from FXIII-B2 linked to the sensor chip. The association rate
constant (ka), dissociation rate constant (kd), and equilibrium dissociation
constant (Kd) were calculated using Biaevaluation software (GE Healthcare).
ELISA-type binding assay
Various concentrations of cFXIII-A2 or rFXIII-A2 were incubated with
0.25 nM FXIII-B2 for 1 hour at 23°C. In the meantime, 100mL biotinylated
monoclonal anti-FXIII-B antibody (1 mg/mL) was added to the wells of
a streptavidin-coated microplate. After a 30-minute incubation, the nonbound
biotinylated antibody was removed by washing. Then, 100 mL of the in-
cubation mixture containing the formed complex was transferred to the wells
and incubated for 1 hour. After extensive washing, the amount of formed
complex was determined by using HRP-labeled anti-FXIII-A antibody and
TMB substrate. The concentration of formed complex was determined by
comparisonwith a standard curve of FXIII-A2B2. TheKdwas calculated using
GraphPad (San Diego, CA) Prism Software (version 5.0).
Calculation and measurement of free FXIII-A in body fluids
The following formula17 was used for the calculations:
½RL ¼
ð½R1 ½L1KdÞ2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½R1 ½L1KdÞ22 4½R½L
q
2
where [R] is the receptor concentration [total FXIII-B2], [L] is the ligand
concentration [total FXIII-A2], and [RL] is the concentration of the complex
[FXIII-A2B2]. For plasma, [total FXIII-B2] and [total FXIII-A2] represent the
mean of total FXIII-B2 and total FXIII-A2
20 concentrations determined in
the plasma of 35 healthy volunteers. Mean and median concentrations
reported earlier were used for the calculation concerning CSF and tears,
respectively.25,26 Kd used in the formula was the mean of Kd values deter-
mined by SPR and the ELISA-type binding assay (4.173 10210 M).
The measurement of free FXIII-A2 concentration in the plasma was
performed on samples immunodepleted of FXIII-A2 present in complex.
Citrated plasma samples from 11 healthy volunteers were depleted of FXIII-
A2B2 and free FXIII-B by immunoabsorption usingmonoclonal anti-FXIII-B
(1) antibody covalently coupled to Sepharose 4B. The complete removal of
complexed FXIII-A2 was veriﬁed by the absence of FXIII-A2B2 in im-
munodepleted plasma samples. In the case of CSF and tears, the difference
between themeasured totalmolar concentrations of FXIII-A2 and FXIII-A2 in
complex was considered the free FXIII-A2 concentration.
Characterization of anti-FXIII-B monoclonal antibodies
Based on preliminary screening experiments, 2 monoclonal anti-FXIII-B
antibodies, anti-FXIII-B(1) and anti-FXIII-B(2), were selected for further
studies. First, they were used for immunoprecipitation of FXIII-B2 from
normal human plasma. The anti-FXIII-B antibodies were coupled to CNBr-
activated Sepharose 4B gel (1.2 mg antibody/1 mL gel). A total of 1 mL
normal human plasma was added to 100 mL antibody-coated beads and
incubated for 2 hours at 23°C. After discarding the plasma, the beads were
washed extensively with phosphate-buffered saline (PBS) (pH 7.2). The
immunoprecipitate was eluted by nonreducing sodium dodecyl sulfate
polyacrylamide electrophoresis (SDS-PAGE) sample buffer at 95°C for
5 min. After centrifugation, the supernatants were reduced by 0.7 M
2-mercaptoethanol. The samples then were subjected to SDS-PAGE and
analyzed by western blotting. The blots were incubated with sheep
polyclonal anti-FXIII-A IgG or rabbit polyclonal anti-FXIII-B antibodies.
The immune reaction was developed by biotinylated anti-sheep IgG and avidin-
biotinylated peroxidase complex (Vectastain ABC kit) or by HRP-conjugated
goat anti-rabbit IgG. The reaction was visualized by enhanced chemilumines-
cence detection (ECL Prime Reagent; GE Healthcare).
Effect of anti-FXIII-B antibodies on the interaction of
FXIII subunits
To test if anti-FXIII-B(2) monoclonal antibody inhibits the complex for-
mation, we set up a modiﬁed ELISA that included the following steps: (1)
binding of biotinylated monoclonal anti-FXIII-B(1) antibody (1 mg/mL in
PBS dilution buffer containing 0.5% BSA and 0.5 M NaCl) to the wells of
a streptavidin-coated microplate, (2) binding of FXIII-B2 (100 ng/mL in
dilution buffer) to the immobilized antibody, (3) the addition of various
concentrations of anti-FXIII-B(2) antibody or buffer to the wells, (4) the
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complex formation of surface-linked FXIII-B2 with FXIII-A2 (100 ng/mL in
dilution buffer), and (5) measurement of the formed FXIII-A2B2 complex by
HRP-labeled anti-FXIII-A antibody. Each incubation step was carried out at
23°C for 60 minutes, and it was followed by extensive washing with 0.05%
Tween 20 in PBS. The amount of bound HRP-conjugated antibody was
determined by TMB substrate at 450 nm.
Fibrin crosslinking by free FXIII-A2 remaining in the plasma
after the removal of FXIII-A2B2 complex
The free FXIII-A2 that remained in the plasma after immunodepletion was
investigated for ﬁbrin crosslinking activity. Plasma samples were clotted by
2 U/mL human thrombin and 10 mM CaCl2 in the absence and presence of
2 mM iodoacetamide at 37°C for 60 minutes. After extensive washing with
saline, the recovered clots were solubilized in reducing SDS-PAGE sample
buffer and the dissolved clots were analyzed by SDS-PAGE. In certain
experiments, thrombin was replaced by batroxobin (11 U/mL), a thrombin-
like snake venom protease that clots ﬁbrinogen by releasing ﬁbrinopeptide A
from the Aa chain of ﬁbrinogen but does not activate FXIII-A2. In this case,
the activation of FXIII by thrombin generated in the plasma in the presence of
Ca21 was inhibited by 10 U/mL hirudin.
Production of recombinant FXIII-B and its 112 sushi domains
FXIII-B and its 2 combined N-terminal sushi domains (SD112) were
transiently expressed in Spodoptera frugiperda Sf9 insect cells using the
InsectDirect kit from Novagen- EMD4Biosciences (Darmstadt, Germany).27
Brieﬂy, F13B ORF (ImaGenes, Berlin, Germany; accession number
BC148333) including the region coding for the signal peptide was ampliﬁed
byPCRuntil the end of FXIII-Bmolecule or SD112.All primers included the
extensions required by the ligation-independent cloning method, and reverse
primers also included a stop codon (depicted in italics). The following primers
were used: forward primer, 59-CAG-GGA-CCC-GGT-ATG-AGG-TTG-
AAA-AAC-CTG-AC-39; reverse primer for FXIII-B, 59-GG-CAC-CAG-
AGC-GTT-TTA-TGT-TCT-TAA-GGG-TTC-TTG-AT-39; reverse primer
for SD112, 59-GG-CAC-CAG-AGC-GTT-CTA-TGT-TTC-ATG-TTC-TTT-
CC-39. The PCR products were cloned into the insect cell expression vector
pIEX/BAC-3 containing anAcNPV-derived hr5 enhancer and an IE1 promoter
and an N-terminal 63His tag. NovaBlue GigaSingle-competent cells
(EMD4Biosciences) were transformed with this construct and the integrity
of the insert of puriﬁed plasmid was veriﬁed by DNA sequencing. Sf9 insect
cells were transfected using polyethylenimine (linear, Mr 25,000 Da)
28 in a 1:4
plasmid-to-polyethylenimine ratio. Subsequently, a 1 3 107/mL suspension
cell culture in BacVector serum free medium (Novagen) was grown for 48
hours at 28°C. The supernatant was concentrated and analyzed by western
blottingusinganti-FXIII-B(2) antibody.The immune reactionwasdevelopedby
biotinylated anti-mouse IgG followed by avidin-biotinylated peroxidase
complex (Vectastain ABC kit) and visualized by chemiluminescence detection.
Epitope mapping by mass spectrometry
Epitopemappingwas performed by themethod ofHager-Braun andTomer in
compact reaction columns (USB Corporation, Cleveland, OH).29 Polyclonal
goat anti-mouse Fc-speciﬁc IgG was bound to CNBr-Sepharose beads, and
then the monoclonal anti-human FXIII-B antibodies were covalently
crosslinked to the immobilized anti-mouse IgG by bis(sulfosuccinimidyl)
suberate. A total of 20mL of washed and drained beads were incubated with
100 mL 10 mg/mL FXIII-B in PBS or with PBS alone at room temperature
for 1 hour. After washing with 33 400 mL 0.1 M Tris-HCl (pH 8.5), 50 mL
1 ng/mL trypsin in 0.1 M Tris-HCl (pH 8.5) was added to the beads and
incubated for 16 hours at 37°C. The supernatant was discarded and the beads
were washed with 3 3 400 mL PBS and 3 3 400 mL 50 mM ammonium
bicarbonate (pH 8.0). Approximately 1 mL of washed beads was mixed with
1 mL of saturated a-cyano-4-hydroxycinnamic acid in ethanol/water/formic
acid (45/45/10 v/v/v) on a matrix-assisted laser desorption/ionization target.
The air-dried mixture was analyzed by matrix-assisted laser desorption/
ionization time-of-ﬂight (MALDI-TOF) mass spectrometry on a Voyager DE
STR instrument (Applied Biosystems, Foster City, CA) in positive reﬂectron
mode.
Results
Equilibrium dissociation constant (Kd) and kinetic parameters
for the FXIII subunit interaction
The Kd for the interaction of FXIII-A2 and FXIII-B2 was determined
by SPR and an ELISA-type binding assay. The representative SPR
sensorgrams (Figure 1A) and the binding curve (Figure 1B) de-
monstrate the binding of rFXIII-A2 to plasma-derived FXIII-B2. As
demonstrated in Figure 1A, the ﬁtting curves nicely followed the
sensorgrams. The same experiments were also carried out with
cFXIII-A2 prepared fromhumanplacenta. TheKd values obtained by
both techniques were similar, in the range of 10210, indicating tight
binding (Table 1). The dissociation rate constants, approximately
2 3 1024 s21, suggest slow dissociation. As expected, there was
hardly any difference between results with rFXIII-A2 and cFXIII-A2.
The binding of rFXIII-A2 to rFXIII-B2 was also tested by SPR.
Figure 1. The binding of various concentrations of
recombinant FXIII-A2 to FXIII-B2. (A) FXIII-B prepared
from plasma was fixed to a CM5 chip and the binding of
FXIII-A2 was followed by the measurement of SPR.
Each sensorgram corresponds to the rFXIII-A2 concen-
tration indicated in the figure. The data were fit to
a simple 1:1 interaction model using the global data
analysis option available within Biaevaluation software.
(B) The binding of rFXIII-A2 to plasma-derived FXIII-B2
was detected in an ELISA-type binding assay; the
binding curve represents the means of 3 separate
experiments not deviating by more than 10%. FXIII-
A2B2/FXIII-B2(t): the molar concentration of measured
formed FXIII-A2B2 was divided by molar concentration
of total added FXIII-B2.
Table 1. Kinetic parameters of FXIII-A2B2 complex formation
n
ka 6 SE
(1/Ms 3 105)
kd 6 SE
(1/s 3 1024)
Kd 6 SE
(M 3 10210)
SPR assay
cFXIII-A2 1 FXIII-B2 7 6.35 6 0.80 2.62 6 0.30 5.17 6 1.44
rFXIIII-A2 1 FXIII-B2 4 5.76 6 0.79 1.69 6 0.08 3.14 6 0.55
rFXIII-A2 1 rFXIII-B2 3 1.38 6 0.30 0.76 6 0.26 6.26 6 2.76
ELISA-type assay
cFXIII-A2 1 FXIII-B2 4 — — 2.93 6 0.68
rFXIIII-A2 1 FXIII-B2 3 — — 5.43 6 0.95
Results are expressed as mean 6 standard error (SE).
rFXIII-B2, recombinant FXIII-B2.
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rFXIII-B2 was produced in insect cells, in which the pattern of
N-glycosylation is different frommammalian cells.30,31 The difference
in N-glycan residues on FXIII-B2 resulting in a protein with a lower
molecular mass did not inﬂuence signiﬁcantly its interaction with
FXIII-A2 (Table 1).
Free FXIII-A2 in the plasma and other body fluids
Using the mean of Kd values measured by the 2 techniques and the
mean total FXIII-A2 and FXIII-B2 concentration, the amount of
complexed FXIII-A2 and free FXIII-A2 in the plasma was calculated
(Table 2). According to the calculation, approximately 1% of the
total FXIII-A2 should exist in free form, not associated with FXIII-
B2. This surprising ﬁndingwas tested experimentally. Eleven human
plasma samples were fully depleted of FXIII-A2B2 and also of free
FXIII-B2 by immunoabsorption using a monoclonal antibody, anti-
FXIII-B(1), that equally reacted with both the free and complexed
forms of FXIII-B2. The complete removal of FXIII-A2B2was proven
by a highly sensitive ELISA, the detection limit of which is 0.003 nM,
which corresponds to 0.004% of average pFXIII-A2B2 concen-
tration.19 In the immunodepleted plasma samples, 1.06 6 0.49
nM free FXIII-A2 was measured; ie, 1.38% 6 0.55% of pFXIII-
A2 existed in free form (Table 2).
To test the validity of the establishedKd, calculated andmeasured
free FXIII-A2 were also compared in CSF and tears, in which FXIII
subunit concentrations were at least 3 magnitudes lower than in the
plasma. In such conditions, one would expect a much higher pro-
portion of free FXIII-A2. Indeed, both the calculated and measured
values were above 80%, and they showed fair agreement.
Free FXIII-A2 in the plasma is functionally intact
To answer the question of whether free FXIII-A2 present in the plasma
is functionally intact, plasma immunodepleted of FXIII-A2B2 was
treated by thrombin and Ca21 and the formed clot was analyzed for
ﬁbrin crosslinking (Figure 2). Fibrin formed in nondepleted plasma
showed complete dimerization of its g chains and the formation of
highly crosslinked a-chain polymers (ap). Fibrin chain crosslinking
was prevented by the FXIIIa inhibitor iodoacetamide. In the im-
munodepleted plasma, the transglutaminase-dependent formation of
g-chain dimers was well detectable, demonstrating that free pFXIII-
A2 can be transformed into an active transglutaminase. As opposed to
nondepleted plasma, no ap was detected on the top of concentrating
gel. This is not surprising; g-chain dimerization is a highly sensitive
indicator of FXIIIa activity, whereas a-chain polymerization requires
much higher FXIIIa concentration and is a much slower process than
g-chain crosslinking.32,33 The ﬁbrin crosslinking pattern in immuno-
depleted plasma corresponds well to the ﬁnding that only approxi-
mately 1%of pFXIIIFXIII-A2 is in free form. The next questionwas if
free FXIII-A2 was in the nonactivated or active form. To address this
question, ﬁbrin clot formation was induced by B moojeni and Ca21 in
immunodepleted plasma. B moojeni cleaves off ﬁbrinopeptide A,
but not ﬁbrinopeptide B, from ﬁbrinogen and fails to activate FXIII.
The activation of FXIII by thrombin generated in the plasma in the
presence of Ca21 was prevented by hirudin. In such a setup, no
ﬁbrin-chain crosslinking occurred, indicating that free FXIII-A2 in
the plasma was in the nonactivated form.
Monoclonal anti-FXIII-B antibody that prevents the interaction
between FXIII subunits
Figure 3A demonstrates the interaction of 2 selected monoclonal
anti-FXIII-B antibodies with FXIII-B present in complex and in free
form. The immunoprecipitate obtained by anti-FXIII-B(1) antibody
cross-reacted with anti-FXIII-A antibody on the western blot,
Table 2. Comparison of calculated and measured free FXIII-A2 in plasma and in other body fluids
Mean/median total
FXIII-B2
Mean/median total
FXIII-A2
FXIII-A2 in complex
calculated
Free FXIII-A2
calculated
% free FXIII-A2
calculated
% free FXIII-A2
measured
Plasma 113.1 nM 69.9 nM 69.2 nM 0.7 nM 1.0 1.38 6 0.55
CSF* 113.0 pM 80.4 pM 3.37 pM 12.9 pM 81.0 95.8
Tears* 45.1 pM 12.8 pM 2.00 pM 24.7 pM 89.5 83.7
Measured plasma free FXIII-A2 concentration was expressed as percentage of total FXIII-A2 concentration. The results represent the mean 6 SD of values measured in
11 individual samples.
*Because the distribution of FXIII subunit concentrations in CSF and tears were nonparametric, in these cases the median values reported in previous publications25,26
were used for the calculations.
Figure 2. Fibrin crosslinking by noncomplexed free FXIII-A2 remaining in the
plasma after removal of FXIII-A2B2 complex by immunodepletion. Plasma was
depleted of FXIII-A2B2 and FXIII-B2 by immunoabsorption on Sepharose-linked
anti-FXIII-B monoclonal antibody that reacted with both free and complexed FXIII-B.
Depleted plasma (DP) and normal plasma (P) were clotted by thrombin (T) in the
presence and absence of the FXIIIa inhibitor iodoacetamide (IA). Depleted plasma
was also clotted by batroxobin (B) in the presence of the thrombin inhibitor hirudin
(H). The fibrin clots were washed and analyzed by SDS-PAGE; fibrin a, b, and g
chains; g-chain dimers (g-g); and high-Mr a-chain polymers (ap) are indicated on the
figure. The table below the gel shows the components of the clotting mixture that
resulted in the fibrin clot shown on the respective lane.
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whereas no such cross-reaction was detected when anti-FXIII-B(2)
antibody was used for immunoprecipitation. The results clearly
indicate that anti-FXIII-B(1) recognizes FXIII-B both in the free and
complexed form, whereas anti-FXIII-B(2) reacts only with the free
form. Furthermore, preincubation of FXIII-B2 with anti-FXIII-B(2)
prevented complex formation with FXIII-A2, whereas anti-FXIII-B(1)
had no such effect (Figure 3B).
Epitope mapping for anti-FXIII-B antibodies
rFXIII-B2 was engineered in insect cells. Due to incomplete
N-glycosylation, themolecularmass of rFXIII-B2 is somewhat lower
than that of its plasma counterpart and rFXIII-B2 moved somewhat
faster in SDS gel than FXIII-B2 prepared from plasma (Figure 4,
lanes 1 and 2). Plasma and rFXIII-B reacted equally well with
anti-FXIII-B(2), whereas there was no reaction with the concen-
trated supernatant of mock-transfected cells (lane 3). The antibody
gave strong reaction with recombinant SD112, the combined ﬁrst
2 N-terminal sushi domains of FXIII-B (lane 4). The results
indicate that the antibody interfering with the interaction of FXIII
subunits binds to an epitope on SD112.
Because efforts to express sushi domains 1 and 2 separately re-
mained unsuccessful, we searched for the epitope reacting with
anti-FXIII-B(2) by using a different technique. Anti-FXIII-B(2) was
covalently linked to Fc-fragment-speciﬁc anti-mouse IgG immobi-
lized on Sepharose gel and incubated with FXIII-B. After exhaustive
digestion with trypsin, the fragments that remained attached to
anti-FXIII-B(2) were identiﬁed by MALDI-TOF mass spectrometry.
We were able to identify 2 tryptic fragments (Figure 5A) with the
sequences that correspond to amino acid positions 90 to 103 and 96 to
103 on the second sushi domain (Figure 5B). The presence of these
overlapping peptides is explained by the Arg95His FXIII-B poly-
morphism.16 The frequency of the His95 allele is approximately 7.5%
in the white population (International HapMap project; www.hapmap.
org), and in the FXIII-B preparation puriﬁed from pooled plasma,
both variants must have been present. The presence of His at position
95 eliminates a trypsin cleavage site, and instead of the peptide
YGCASGYK, a longer peptide with the sequence IQENMHYGC-
ASGYKwas recovered.The results locate the epitope for anti-FXIII-B
(2) antibody to the octapeptide present in the second sushi domain
between positions 96 and 103. Using the same technique, the epitope
for anti-FXIII-B(1) antibody, which did not interfere with complex
formation, was located to the peptide sequence 405 to 412
(CNEYYLLR) in seventh sushi domain.
Discussion
Unequivocal results obtained by 2 different techniques showed that
the Kd for the association of the 2 types of FXIII subunit is in the
range of 10210 M, which is magnitudes lower than the values
published in earlier reports.15,16 The estimated Kd is in the range of
high-afﬁnity antigen-antibody interaction and suggests very tight
binding between FXIII-A2 and FXIII-B2. It has been generally
accepted that FXIII-A2 in the plasma is fully complexed with FXIII-
B. However, calculations based on the estimated Kd and the FXIII
subunit concentrations present in the plasma suggested that, in spite
of the tight binding, aminor fraction of FXIII-A2 (approximately 1%)
exists in the free noncomplexed form. The presence of free FXIII-A2
in plasma was also conﬁrmed experimentally. In tears and CSF at
FXIII subunit concentrations aminimum of 3magnitudes lower than
in plasma, the proportion of free FXIII-A2 was much higher. The
established Kd was also validated by the fair agreement between
calculated and measured free FXIII-A2 in the 3 body ﬂuids.
It was also shown that the measured free FXIII-A2 is neither
a degraded nor an activated form of FXIII; it is functionally active,
and when activated by thrombin and Ca21, it can crosslink ﬁbrin. At
this stage, one can only offer speculations on the physiological sig-
niﬁcance of free FXIII-A2 in the plasma. FXIII-A2 in the absence
Figure 3. The differential binding of 2 monoclonal anti-FXIII-B antibodies to
complexed and free FXIII-B. (A) FXIII-B was immunoprecipitated from human
plasma by 2 monoclonal anti-FXIII-B antibodies and the presence of FXIII-B and
FXIII-A, and the immunoprecipitates were detected by western blotting using polyclonal
anti-FXIII-B or anti-FXIII-A antibodies on separate blots. FXIII-A was present in the
immunoprecipitate obtained by anti-FXIII-B(1) but absent when anti-FXIII-B(2) was
used for immunoprecipitation. (B) the concentration-dependent inhibition of FXIII-A2B2
complex formation by anti-FXIII-B(2), but not by anti-FXIII-B(1), antibody was
demonstrated in an ELISA-type assay as described in “Effect of anti-FXIII-B
antibodies on the interaction of FXIII subunits” in “Methods.” The label on the y-axis
(optical density [OD] 450 nm) is a measure of FXIII-A2B2 complex formation.
Figure 4. The binding of anti-FXIII-B(2) antibody to recombinant FXIII-B and its
combined 112 sushi domains (SD112). FXIII-B and SD112 were expressed in
insect cells as described in the text. Cell culture supernatants were concentrated and
analyzed by western blotting. Lane 1: FXIII-B isolated from the plasma (the faint
band below FXIII-B corresponds to a proteolytic product); lane 2: supernatant of
cultured cells expressing rFXIII-B; lane 3: supernatant of mock-transfected cells;
lane 4: supernatant of cells expressing SD112.
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of FXIII-B2 does not need the removal of activation peptide for
activation. Noncleaved FXIII-A2 goes through a slow progressive
activation at Ca21 andNaCl concentrations present in the plasma, and
ﬁbrinogen might promote this nonproteolytic activation. Years ago,
a low-grade “constitutive” ﬁbrin and ﬁbrinogen crosslinking activity
of nonactivated pFXIII was described.34 One wonders if this con-
stitutive activity could be associatedwith the free fraction of FXIII-A2.
This presumption seems to be contradicted by the ﬁnding that in
immunodepleted plasma containing only free FXIII-A2, ﬁbrin formed
by batroxobin was not crosslinked. However, any nonproteolytically
activated free FXIII-A2 might bind to cellular elements or to ﬁbrin
(ogen) ﬁbrils and might be cleared from the plasma. It is also possible
that in newly formed ﬁbrin, this more easily activated fraction of
pFXIII contributes to the rapid crosslinking of ﬁbrin g chains, which
needs only a minute amount of FXIIIa.35
FXIII-B is N-glycosylated at Asn142 and Asn525, which reside
in the third and ninth sushi domains, respectively.36,37 Neither the
removal of carbohydrate residues from FXIII-B by neuraminidase
or N-glycosidase F nor the different carbohydrate side chain on
rFXIII-B expressed in insect cells prevented the formation of A2B2
complex.10,15 In the present experiments, the Kd for the binding of
plasma-derived FXIII-B2 to rFXIII-A2 did not differ signiﬁcantly
from the Kd for the interaction of rFXIII-B2 and rFXIII-A2. These
ﬁndings strongly suggest that the binding epitope(s) responsible for
the interaction with FXIII-A2 must reside in the protein part.
To locate the epitope on FXIII-B responsible for the interaction
with FXIII-A, Souri et al produced various truncated rFXIII-Bs of
various lengths.10 They demonstrated that those truncated FXIII-B
subunits that lacked the ﬁrst sushi domain were not able to form
a complex with FXIII-A. Just like us, they were not able to express
isolated sushi domain 1. We took a different approach by producing
an anti-FXIII-B monoclonal antibody that interacted only with free
FXIII-B2 and prevented its complex formation with FXIII-A2. The
antibody recognized FXIII-B on western blots; that is, it reacted with
a sequential epitope. The ﬁnding that it reacted with SD112 conﬁrms
that the N-terminal part of the molecule is involved in the interaction
with FXIII-A2. By the combination of immunoabsorption and
MALDI-TOF techniques, it was demonstrated that epitope for the
antibody is in the peptide YGCASGYK spanning positions 96 to 103
in the second sushi domain. The other antibody that reacted with the
seventh sushi domain failed to inﬂuence the interaction of FXIII
subunits. The ﬁndings of Souri et al and our results suggesting the
interaction site for complex formation on the ﬁrst and second sushi
domains of FXIII-B, respectively, are not necessarily contradictory.
The lack of the ﬁrst sushi domain might inﬂuence the orientation/
conﬁguration of the second sushi domain and distort the binding site.
On the other hand, the antibody reacting with the second sushi domain
might make the binding site on the ﬁrst sushi domain inaccessible for
FXIII-A2 by steric hindrance. Further experiments are needed to
pinpoint the epitope(s) on SD112 of FXIII-B that are involved in the
formation of FXIII-A2B2 complex.
The combination of the antibodies reacting onlywith free FXIII-B2
and with both free and complexed FXIII-B2 provides the potential of
developing a sandwichELISA for themeasurement of freeFXIII-B2 in
the plasma. Such an assay could be useful for the determination of
rFXIII-A2 binding capacity in substituted patients.
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